Czech
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Strana 1 z 39 Výsledek
Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. A 67-year-old Japanese man who underwent a hepatectomy developed peritoneal dissemination. A combination therapy of
Uracil-Tegafur-induced pleural effusion following lung cancer surgery.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
The patient was a 75-year-old female with a history of no smoking. Under a diagnosis of lung cancer, she underwent a right lower lobectomy in March 2008. She was started on oral Uracil-Tegafur (UFT) (400 mg/day) from April and in May developed fatigue, respiratory discomfort, and tachycardiac atrial
Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
Standard chemotherapy for advanced biliary tract cancer has not been established. The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of uracil-tegafur (UFT) and doxorubicin in patients with unresectable advanced biliary tract
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
CONCLUSIONS
UFT 300 mg/m2/day and leucovorin 90 mg/day could be administered safely to patients with advanced biliary cancer with good performance status; however, this combination and schedule of 28-day administration has no activity in this disease.
OBJECTIVE
To determine the activity and evaluate
Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
The combination of oral uracil/tegafur (UFT) plus leucovorin (LV) is widely accepted as adjuvant chemotherapy for stages II and III of colorectal cancer. However, the clinical compliance of Japanese patients with this regimen has not been clearly elucidated to date.
METHODS
A total of 40
A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
The objective of this Phase II study was to define the response rate, safety profile, and toxicity of oral uracil and ftorafur (UFT) with leucovorin (UFT/LV) as a palliative treatment for patients with squamous cell carcinoma of the head and neck (SCCHN).
METHODS
Patients with metastatic
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
To determine the activity and evaluate the toxicity of uracil and tegafur in a 4:1 molar concentration (UFT; Taiho Pharmaceutical Ltd, Tokyo, Japan) plus oral calcium leucovorin in the treatment of patients with advanced colorectal carcinoma.
METHODS
Forty-five patients with advanced,
Investigation of anti-fatigue effect and simultaneous determination of eight nucleosides in different parts of velvet antler in red deer and sika deer.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Velvet antler (VA) is crucial and precious nourishment in China and some countries in Southeast Asia. It has several pharmacological effects such as alleviating fatigue and strengthening the body. The incidence of fatigue syndrome has increased gradually. Thus, VA can be a potential source of
A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
A phase I and pharmacokinetics study of oral uracil, ftorafur, and leucovorin was performed in patients with advanced cancer. Uracil plus ftorafur (UFT) was given in a 4:1 molar ratio in three divided doses for 28 consecutive days. Patient cohorts were treated at 200, 250, 300, and 350 mg/m2 of UFT
A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
Ftorafur is an orally available prodrug of 5-fluorouracil (5-FU). Its combination with uracil in a molar ratio of 1:4 (UFT) increases the 5-FU concentration in tumor cells compared with ftorafur alone. Paclitaxel has a broad spectrum of activity against solid tumors and synergic effects
[Successful management for advanced renal cell carcinoma under combination therapy with human lymphoblastoid interferon-alpha and UFT (mixture of tegafur and uracil): a case report].
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
We report a case of renal cell carcinoma in a 76-year-old man with pulmonary metastasis and tumor thrombus in inferior vena cava. The patient responded to the combination therapy with a small amount of HLBI (human lymphoblastoid interferon-alpha) and UFT (1:4 mixture of tegafur and uracil). HLBI was
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Although UFT 300 mg/m2/day and leucovorin 90 mg/day administered orally in divided doses administered every 8 hours for 28 days repeated every 35 days could be administered safely to patients with advanced hepatomas and good performance status, this combination and schedule has limited activity in
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
We previously reported results of a Phase II trial of UFT [Taiho Pharmaceutical Ltd., Tokyo, Japan; (BMS-200604) Bristol-Myers Squibb, Princeton, NJ], an oral 4:1 molar concentration of uracil and tegafur, plus oral leucovorin for metastatic colorectal carcinoma (Pazdur et al., J. Clin. Oncol.
Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
We previously reported that uracil-tegafur with oral leucovorin (UFT/LV) treatment for elderly patients (aged ≥ 75 years) was well-tolerated in a phase II study. In the present study, the efficacy and safety of a modified (1-week shorter administration period) UFT/LV schedule combined with
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC). Metronomic chemotherapy using tegafur/uracil (4:1 molar ratio), an oral fluoropyrimidine, has been shown to enhance the anti-tumor effect
Nejúplnější databáze léčivých bylin podložená vědou
- Funguje v 55 jazycích
- Bylinné léky podporované vědou
- Rozpoznávání bylin podle obrázku
- Interaktivní mapa GPS - označte byliny na místě (již brzy)
- Přečtěte si vědecké publikace související s vaším hledáním
- Hledejte léčivé byliny podle jejich účinků
- Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty
Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu
